Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Identify effective ways to increase income to pay off debt. Maximize your earnings and take control of your financial future.
22,636 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Bumble delivered a beat on Q4 2025 revenue as it unveiled Bee, an AI dating concierge. The move coincided with a dram...
Lawmakers unveil a plan centered on a common-sense approach housing affordability to address supply and cost hurdles....
When energy costs rise, investors often look for EV players that could benefit. This article unpack Rivian's path to ...
eXp World Holdings reports a modest rise in its global agent base for 2025, but the real driver is exp’s quiet flex: ...
As voice interfaces become a staple in shopping, SoundHound AI could rise as a key AI infrastructure layer. This arti...
Zeta Global is accelerating its AI-powered strategy, unlocking new growth channels and investor potential. This artic...
Medicare's day-count cliffs push hospital costs $434 per day after day 60, rising to $868 per day after day 90. The p...
As 2026 looms, investors hunt for clarity in a volatile crypto landscape. From ETH buy-ins by top analysts to evolvin...
As XRP fluctuates in a tight range, traders and analysts scrutinize whether the price prediction: reach $100? is conc...
Mizuho ups UnitedHealth's price target to $440, citing easing medical loss ratio pressures and a turning Medicare Adv...
A biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...